\n
![\"EarthSnap\"\/](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/05\/earthsnap-banner-news.webp.webp\")
\n<\/a><\/p>\n
However, an ordinary amino acid has shown early promise in paving a new path forward. Additionally, it is already consumed by millions of people every day.<\/p>\n
Everyday amino acid enters<\/p>\n
The compound is arginine<\/a>, an amino acid your body uses to build proteins. It is sold cheaply at any drugstore and found in everyday foods like chicken, nuts, and seeds.<\/p>\n Kanako Fujii and Professor Yoshitaka Nagai of Kindai University<\/a> spent years observing the effects of the amino acid on protein clumps that affect the Alzheimer\u2019s brain.<\/p>\n The answer was found within both flies and mice.<\/p>\n Slowing the formation of plaques<\/p>\n Amyloid-beta, or A\u03b2, is the protein at the heart of Alzheimer\u2019s. <\/p>\n In a healthy brain, individual A\u03b2 molecules drift around without much trouble. But once things start to go wrong, they stick to each other. <\/p>\n First, they clump into small toxic clusters, then into the dense amyloid plaques that show up under the microscope as the disease\u2019s signature.<\/p>\n Arginine is thought to act as a chemical chaperone. In doing so, it may nestle up to a misbehaving protein and help it stay properly folded, prohibiting clumping. <\/p>\n The broader concept was established years ago in a foundational paper<\/a> on protein conformational diseases.<\/p>\n In a test tube, the team poured arginine onto a notoriously sticky version of A\u03b2 called A\u03b242 and watched the aggregation slow. <\/p>\n The more arginine they added, the fewer clumps formed. This produced a clean, dose-dependent effect.<\/p>\n Moving beyond the lab dish<\/p>\n Lab dishes are easy to understand, but living animals are not. Because of this, the team began to observe two well-established Alzheimer\u2019s models. <\/p>\n The first was a fruit fly engineered to produce a particularly aggressive form of human A\u03b242, carrying a mutation that makes the protein especially prone to clumping. <\/p>\n For the second, they used a mouse line called AppNL-G-F, which carries three different familial Alzheimer\u2019s mutations stacked on top of each other.<\/p>\n In both, animals drank arginine in their water for weeks. Flies proved to lived longer. Additionally, the mice did much better, offering new and important insight.<\/p>\n Less damage, improved performance<\/p>\n Brains from arginine-treated AppNL-G-F mice carried fewer of the dense plaques<\/a> that mark advanced disease. <\/p>\n Levels of insoluble A\u03b242 \u2013 the form that sticks together hardest and resists clearance \u2013 dropped as well.<\/p>\n Treated animals also acted differently. Untreated AppNL-G-F mice tend to flunk standard memory and behavior tasks. <\/p>\n Also, the ones on arginine performed measurably better in those same tests. A reduction in plaques on a microscope slide is one thing. <\/p>\n A mouse acting more like a healthy mouse is something else entirely. That\u2019s where a treatment starts to show promise for human subjects. <\/p>\n Calmer brain immune cells<\/p>\n Plaques aren\u2019t the only problem in Alzheimer\u2019s. Resident immune cells called microglia react to amyloid buildup by pumping out inflammatory signals. <\/p>\n Over time, that neuroinflammation can damage neurons on its own, as detailed in a published review<\/a> of the field.<\/p>\n In the arginine-treated mice, genes that drive brain inflammation were less active \u2013 suggesting the chemical signals microglia use to call in reinforcements were quieter. <\/p>\n Less amyloid and quieter immune responses equate to better behavior. These were three readouts moving in the right direction all at once.<\/p>\n A pre-approved drug<\/p>\n Arginine isn\u2019t a mystery molecule. It\u2019s already used clinically in Japan for unrelated conditions, has a long human safety record, and crosses the blood-brain barrier without much fuss. <\/p>\n Most Alzheimer\u2019s drug candidates die in early human trials over toxicity or absorption problems. <\/p>\n Fortunately, arginine has cleared those hurdles already. Repurposing it for Alzheimer\u2019s would skip years of preliminary safety testing and cost a fraction of what the antibody therapies now on the market run.<\/p>\n \u201cGiven its excellent safety profile and low cost, arginine could be rapidly translated to clinical trials for Alzheimer\u2019s and potentially other related disorders,\u201d said Nagai.<\/p>\n Before human trials are conducted<\/p>\n All of this happened in flies and mice carrying inherited Alzheimer\u2019s<\/a> , a setup that doesn\u2019t fully represent all Alzheimer\u2019s cases.\u00a0<\/p>\n Whether these results translate to that more common form of the disease remains to be seen. <\/p>\n The doses used in the animals were also optimized for research and will need to be calibrated before any human trial can begin.<\/p>\n Cheaper path for treatment<\/p>\n Until this study, no one had shown that oral arginine could provide so much relief. <\/p>\n It was unknown to reduce amyloid plaques, lower insoluble A\u03b242, calm brain inflammation, and rescue behavior in a mouse model carrying multiple familial Alzheimer\u2019s mutations.<\/p>\n What the work does is provide clinicians an option already cleared for human use, ready for proper trials at a fraction of the cost of the antibody class. <\/p>\n The next disease-modifying treatment for Alzheimer\u2019s may not come from a biotech lab at all. It may come from a bottle that\u2019s been sitting in pharmacies for decades.<\/p>\n The study is published in the journal Neurochemistry International<\/a>.<\/p>\n \u2014\u2013<\/p>\n Like what you read?\u00a0Subscribe to our newsletter\u00a0<\/a>for engaging articles, exclusive content, and the latest updates.<\/p>\n Check us out on\u00a0EarthSnap<\/a>, a free app brought to you by\u00a0Eric Ralls<\/a>\u00a0and Earth.com.<\/p>\n \u2014\u2013<\/p>\n","protected":false},"excerpt":{"rendered":"The Alzheimer\u2019s drugs approved in recent years are administered through IV infusions, not pharmacy bottles. Treatment is difficult,…\n","protected":false},"author":2,"featured_media":949307,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4318],"tags":[105,4434,16,15],"class_list":{"0":"post-949306","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-nutrition","8":"tag-health","9":"tag-nutrition","10":"tag-uk","11":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116547253539891888","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/949306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=949306"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/949306\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/949307"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=949306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=949306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=949306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}